A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.

Loading...
Thumbnail Image
Authors
Marlow, R.
Kuriyakose, S.
Mesaros, N.
Han, H.H.
Tomlinson, Richard
Faust, S. N.
Snape, M. D.
Pollard, A. J.
Finn, A.
Journal
Vaccine
Type
Journal Article
Randomized Controlled Trial
Publisher
Elsevier
Rights
Archived with thanks to Vaccine. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/
To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) as a pre-school booster in 3-4 year old children as compared to dTap-IPVR (Repevax, Sanofi Pasteur), when co-administered with mumps-measles-rubella vaccine (MMRV).
Citation
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. 2018, 36 (17):2300-2306 Vaccine
Note